PropertyValue
?:abstract
  • The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), originated in Wuhan, China, in December 2019 has become a major concern all over the world and is named as Coronavirus disease 2019 (COVID-19) by the WHO The virus has spread rapidly in the world creating a pandemic In India the foremost case was reported on January 30, 2020 in Kerala state and now the number has reached up to more than 90000 cases as of May 17, 2020, out of which more than 2800 patients died and more than 34000 patients have recovered Owing to this, India has implemented several precautionary measures to avoid the spread of disease in the beginning stage On March 24, 2020, the Indian government authorities announced nationwide lockdown to be implemented from March 25, 2020 to break the chain of transmission of the disease To date there is no specific treatment proven to be effective for COVID-19 To manage patients, the symptomatic treatment is generally given Supportive care systems like oxygenation and ventilation are provided along with some anti-viral drugs, anti-malarial drugs like hydroxychloroquine etc These kinds of measures are not effective and sufficient in treating the disease The severe impact of pandemic is increasing day by day Hence there is a need to switch to such treatment option which will reduce and recover the number of patients in shorter time In this review, we try to uncover the current scenario of COVID-19 in India with respect to the factors viz transmission, diagnosis, management protocols, lockdown effects and convalescent plasma therapy which might be an immediate potential strategy against COVID-19 combat © 2020, World Research Association All rights reserved
is ?:annotates of
?:creator
?:journal
  • Disaster_Advances
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • COVID-19;current scenario in India and convalescent plasma therapy as combating approach
?:type
?:who_covidence_id
  • #896497
?:year
  • 2020

Metadata

Anon_0  
expand all